IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to an adaptive immune response in the host and the formation of anti-SARS-CoV-2 specific antibodies. While IgG responses against SARS-CoV-2 have been characterized quite well, less is known about IgA. IgA2 activates immune cells and induces inflammation and neutrophil extracellular trap (NET) formation which may contribute to organ injury and fatal outcome in SARS-CoV-2-infected patients. SARS-CoV-2 spike protein specific antibody levels were measured in plasma samples of 15 noninfected controls and 82 SARS-CoV-2-infected patients with no or mild symptoms, moderate symptoms (hospitalization) or severe disease (intensive care unit, ICU). Antibody levels were compared to levels of C-reactive protein (CRP) and circulating extracellular DNA (ecDNA) as markers for general inflammation and NET formation, respectively. While levels of SARS-CoV-2-specific IgG were similar in all patient groups, IgA2 antibodies were restricted to severe disease and showed the strongest discrimination between nonfatal and fatal outcome in patients with severe SARS-CoV-2 infection. While anti-SARS-CoV-2 IgG and IgA2 levels correlated with CRP levels in severely diseased patients, only anti-SARS-CoV-2 IgA2 correlated with ecDNA. These data suggest that the formation of anti-SARS-CoV-2 IgA2 during SARS-CoV-2 infection is a marker for more severe disease related to NET formation and poor outcome.

[1]  J. Crothers,et al.  Kinetics and isotype assessment of antibodies targeting the spike protein receptor‐binding domain of severe acute respiratory syndrome‐coronavirus‐2 in COVID‐19 patients as a function of age, biological sex and disease severity , 2020, Clinical & translational immunology.

[2]  P. Saldiva,et al.  SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.

[3]  M. Neurath,et al.  Vascular occlusion by neutrophil extracellular traps in COVID-19 , 2020, EBioMedicine.

[4]  M. Rudelius,et al.  Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy , 2020, Circulation.

[5]  N. Zhong,et al.  Characteristics and roles of severe acute respiratory syndrome coronavirus 2‐specific antibodies in patients with different severities of coronavirus 19 , 2020, Clinical and experimental immunology.

[6]  L. Risch,et al.  Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies , 2020, medRxiv.

[7]  Galit Alter,et al.  Dynamics and significance of the antibody response to SARS-CoV-2 infection , 2020, medRxiv.

[8]  R. Sanders,et al.  Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses , 2020, bioRxiv.

[9]  D. Unutmaz,et al.  Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19 , 2020, medRxiv.

[10]  C. Takiya,et al.  The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19) , 2020, Scientific Reports.

[11]  Robert A. Campbell,et al.  Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome , 2020, Blood.

[12]  J. Pawlotsky,et al.  SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients , 2020, Intensive Care Medicine.

[13]  John D Lambris,et al.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.

[14]  J. Pačes,et al.  COVID-19 and the immune system. , 2020, Physiological research.

[15]  Yajuan Li,et al.  Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.

[16]  N. Zhong,et al.  Characteristics and roles of SARS-CoV-2 specific antibodies in patients with different severities of COVID-19 , 2020 .

[17]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[18]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[19]  Paolo Maria Matricardi,et al.  The first, holistic immunological model of COVID‐19: Implications for prevention, diagnosis, and public health measures , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[20]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[21]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[22]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[23]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[24]  Guillermo J. Lagos-Grisales,et al.  Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.

[25]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[26]  G. Schett,et al.  IgA subclasses have different effector functions associated with distinct glycosylation profiles , 2020, Nature Communications.

[27]  J. Ravetch,et al.  Functional diversification of IgGs through Fc glycosylation. , 2019, The Journal of clinical investigation.

[28]  J. Jansen,et al.  Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG , 2019, Front. Immunol..

[29]  Z. Vadasz,et al.  Innate immune-responses and their role in driving autoimmunity. , 2019, Autoimmunity reviews.

[30]  D. Baeten,et al.  The inflammatory function of human IgA , 2018, Cellular and Molecular Life Sciences.

[31]  M. van Egmond,et al.  IgA Complexes in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis Induce Neutrophil Extracellular Traps via FcαRI , 2016, The Journal of Immunology.

[32]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[33]  Cornelia L Dekker,et al.  Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching , 2016, eLife.

[34]  E. Cornelio Situation Report , 2012 .

[35]  J. Köhl,et al.  The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. , 2012, Immunobiology.

[36]  P. Woo,et al.  Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.

[37]  J. Lund,et al.  FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy , 1997 .

[38]  J. Lund,et al.  FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. , 1997, Blood.